Technology News and Research

RSS

Partnership to improve TB vaccine, Bacillus Calmette-Guérin (BCG)

Crucell N.V.and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, announced today a new collaboration on the pre-clinical and clinical development of candidate tuberculosis (TB) vaccines. Aeras has agreed to provide Crucell up to USD$2.9 million contingent upon meeting certain development milestones, for development of TB vaccine candidates.

25 Mar 2004

A debate over the origins of what is sometimes called "junk" DNA has been settled

A debate over the origins of what is sometimes called "junk" DNA has been settled by research involving scientists at the Center for Advanced Research in Biotechnology (CARB) and a collaborator, who developed rigorous proof that these mysterious sections were added to DNA "late" in the evolution of life on earth, after the formation of modern-sized genes, which contain instructions for making proteins.

25 Mar 2004

Brain signals could act as remote controls

In their first human studies of the feasibility of using brain signals to operate external devices, researchers at Duke University Medical Center report that arrays of electrodes can provide useable signals for controlling such devices. The research team is now working to develop prototype devices that may enable paralyzed people to operate "neuroprosthetic" and other external devices using only their brain signals.

25 Mar 2004

iCAD issued with Fulcrum mammography film digitizer patent

iCAD, Inc., which designs, develops and markets Computer Aided Detection (CAD) imaging technology and systems for the early detection of breast cancer and other medical applications, today announced that the U.S. Patent and Trademark Office has issued the Company two patents for its Fulcrum mammography film digitizer and technology.

24 Mar 2004

British company to launch "super bug tester" into UK hospitals

MRSA is the first test to be developed from Acolyte’s BacLite® testing platform. BacLite reduces the time for identifying both the type of bacteria and, more importantly, the antibiotic sensitivity of the bacteria from the current 3-4 day standard to just 2-5 hours. This time advantage will mean clinicians will be able to treat, much more effectively, serious bacterial infections and prevent potentially fatal complications, such as sepsis and septic shock, from developing.

24 Mar 2004

FDA Approves Pre-Filled Pre-Mixed Fertility Medication

The U.S. Food and Drug Administration (FDA) today announced approval of Follistim®-AQ TM cartridge (follitropin beta injection) in the United States. Follistim-AQ cartridge is the first follicle stimulating hormone (FSH) treatment available in a pre-filled, pre-mixed solution, eliminating the need for patients to mix one or more vials of medication.

24 Mar 2004

LAM Pharmaceutical receives approval to sell it's wound gel in China

LAM Pharmaceutical, a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that the Chinese State Food and Drug Administration ("SFDA") has granted approval for the importation and sale of its patented LAM IPM Wound Gel(TM) in China

24 Mar 2004

Carbon Dioxide may be used in medical implants

Carbon dioxide, an environmentally friendly solvent for dyeing and dry cleaning, may become a valuable new tool for making medical implants, according to a study at Ohio State University.

23 Mar 2004

Risk Assessment of Diabetic Retiopathy Improved by Screening Methods

Eli Lilly and Company as part of a continued commitment to innovation in the area of diabetes, announced today the creation of a strategic relationship with EyeTel Imaging, Inc. to improve screening and detection of diabetic retinopathy, one of the potentially devastating diabetic microvascular complications. The agreement, which expands the relationship between the two companies, will provide EyeTel with on-going operational support from Lilly, allowing EyeTel to provide primary care physicians access to state-of-the-art patient risk assessment tools and education programs.

23 Mar 2004

EU gives 32 million Euro for vaccines to stop tuberculosis

The European Commission today launched the largest-ever collaborative tuberculosis (TB) initiative for World TB-day, March 24. Fifty-two research teams from academia and industry from 15 European and African countries are joining forces with the European Commission to help eradicate TB. Globally, TB kills 2 million people a year, with one-third of the world's population currently infected with the bacillus, Mycobacterium tuberculosis (Mtb). While most cases and deaths occur in developing countries, resistant Mtb strains are mainly found among the poorest people in developed countries, as incomplete treatment increases drug resistance. The European Union is confronting the re-emerging threat of TB by investing €32 million in two overlapping research projects. This cash will be used in an accelerated effort to develop new, effective vaccines to fight TB.

23 Mar 2004

Stem cell research that could help diabetics

University of Florida adult stem cell experts have restored normal blood sugar levels in diabetic mice for three months by chemically coaxing bone marrow cells to produce insulin, a hormone normally made in the pancreas.

22 Mar 2004

Anti-blood clotting OJ from University of Liverpool

An anti-blood clotting drink has been developed by an up-and-coming biotechnology business based at the University of Liverpool’s Business Incubator, MerseyBIO. Provexis, a medical food company, is in the final stages of its large-scale trial on the new orange juice drink that has been shown to lower the chance of blood clots and thereby reduce risk of heart attack, stroke and the development of deep vein thrombosis.

22 Mar 2004

New resorbable beta-tricalcium phosphate bone void filler

Therics, Inc., a subsidiary of Tredegar Corporation, announced that it has received FDA clearance to market a new resorbable beta-tricalcium phosphate bone void filler device used to treat osseous defects of the skeletal system.

22 Mar 2004

DNA repair enzymes to fight cancer

The body has a set of DNA repair enzymes that clean up damage to the genome, to reduce potential problems. Many commonly used cancer chemotherapies work by alkylating DNA. However, the DNA repair enzymes are just as capable of repairing this alkylation as if it were damage from any other source, and so they act to overcome the effects of the therapy, reducing its effectiveness.

22 Mar 2004

Scientists identify genetic changes during infection by tuberculosis

Researchers at the Center for Biomedical Inventions at UT Southwestern Medical Center at Dallas have identified the genetic changes that Mycobacterium tuberculosis, the bacterium that causes tuberculosis, undergoes during infection of a living host.

22 Mar 2004

New Treatment for Chronic Head Pain

Dr. Levy pioneered a procedure known as supraorbital nerve stimulation or SOS, in which neurotransmitters are implanted into the forehead to block head pain. Tiny wires are burrowed under the skin until the precise location of pain is marked by a tingling response to electrical charge. The wires are kept in place for a week, and if pain is lessened and the patient is comfortable with the technology, neurotransmitters are surgically implanted under local anesthesia. The patient is able to control pain relief by manually adjusting the level of electrical stimulation through a hand held device.

22 Mar 2004

New drug to treat urinary tract infections, a step closer

Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.

22 Mar 2004

Information about Lasik eye surgery, a new technique to treat cataracts

Using an advanced microsurgical technology, called Aqualase(R), a New York eye surgeon is now able to use a procedure to essentially "wash" cataracts away. "By using Aqualase(R) to treat my cataract patients, I am able to dissolve the clouded lens with pulses of warm, naturally balanced salt water solution in order to 'wash away' the lens layer by layer," said Satish Modi, M.D., F.R.C.S. ( C ), a leading ophthalmic surgeon in Poughkeepsie.

22 Mar 2004

New surgical glove alleviates need for "double gloving"

A unique, high-sensitivity, double surgical glove that saves time and money will be debuted at the Association of Operating Room Nurses (AORN) Congress in San Diego, March 20-25. The glove was developed by Bio-Barrier Inc., an infection control technology company based in Los Angeles. The new glove features two separate layers originating from a single cuff at the wrist.

22 Mar 2004

Liverpool scientist presents chronic illness study to House of Commons

A social scientist from the University of Liverpool has visited the House of Commons to present preliminary findings of an innovative research project to MPs.

22 Mar 2004